Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$70.06 -1.6%	$71.48	$28.04 ▼ $117.33	$7.43B	0.19	1.14 million shs	1.01 million shs
JAZZ Jazz Pharmaceuticals	$108.50 -1.6%	$107.84	$95.49 ▼ $148.06	$6.57B	0.33	834,460 shs	478,127 shs
MDCO Medicines	$84.90	$84.90	$17.81 ▼ $84.98	$6.77B	1.1	9.55 million shs	N/A
RPRX Royalty Pharma	$34.84 -1.2%	$32.82	$24.05 ▼ $35.38	$19.59B	0.48	3.61 million shs	3.52 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	0.00%	+0.66%	-4.50%	+25.08%	+114.64%
JAZZ Jazz Pharmaceuticals	0.00%	-2.37%	+2.29%	-21.35%	-2.27%
MDCO Medicines	0.00%	0.00%	0.00%	0.00%	0.00%
RPRX Royalty Pharma	0.00%	+3.14%	+5.19%	+6.32%	+28.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CORT Corcept Therapeutics	4.646 of 5 stars	3.5	1.0	0.0	4.2	3.3	4.2	1.9
JAZZ Jazz Pharmaceuticals	4.9622 of 5 stars	4.5	2.0	0.0	4.0	3.3	3.3	3.1
MDCO Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	4.7192 of 5 stars	3.6	1.0	3.3	3.7	3.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CORT Corcept Therapeutics	3.00	Buy	$138.25	97.33% Upside
JAZZ Jazz Pharmaceuticals	2.92	Moderate Buy	$184.00	69.59% Upside
MDCO Medicines	0.00	N/A	N/A	N/A
RPRX Royalty Pharma	3.25	Buy	$47.33	35.86% Upside

Current Analyst Ratings Breakdown

Latest MDCO, RPRX, CORT, and JAZZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
6/3/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
5/16/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$51.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$182.00 ➝ $172.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$167.00 ➝ $155.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$176.00 ➝ $147.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$183.00 ➝ $166.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$200.00 ➝ $200.00
5/6/2025	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$135.00
5/6/2025	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
4/10/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$210.00 ➝ $210.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CORT Corcept Therapeutics	$685.45M	10.84	$1.03 per share	67.96	$4.92 per share	14.24
JAZZ Jazz Pharmaceuticals	$4.06B	1.62	$22.10 per share	4.91	$59.36 per share	1.83
MDCO Medicines	$6.14M	1,102.36	N/A	N/A	($0.30) per share	-283.00
RPRX Royalty Pharma	$2.26B	8.65	$4.39 per share	7.94	$17.94 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CORT Corcept Therapeutics	$106.14M	$1.16	55.60	37.87	N/A	22.35%	24.54%	20.24%	7/28/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$414.83M	$7.50	15.28	5.80	1.04	11.60%	29.30%	9.72%	7/30/2025 (Estimated)
MDCO Medicines	-$123.16M	-$2.91	N/A	N/A	N/A	N/A	N/A	-25.70%	N/A
RPRX Royalty Pharma	$858.98M	$1.85	24.03	7.17	2.31	37.94%	24.40%	14.01%	8/6/2025 (Estimated)

Latest MDCO, RPRX, CORT, and JAZZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	RPRX Royalty Pharma	$0.99	$1.06	+$0.07	$0.41	$724.69 million	$839.00 million
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDCO Medicines	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.53%	N/A	47.57%	5 Years

Latest MDCO, RPRX, CORT, and JAZZ Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/21/2025	RPRX Royalty Pharma	quarterly	$0.22	2.7%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CORT Corcept Therapeutics	0.01	3.70	3.64
JAZZ Jazz Pharmaceuticals	1.46	4.26	3.74
MDCO Medicines	21.45	0.77	0.77
RPRX Royalty Pharma	0.64	1.44	1.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CORT Corcept Therapeutics	93.61%
JAZZ Jazz Pharmaceuticals	89.14%
MDCO Medicines	N/A
RPRX Royalty Pharma	54.35%

Insider Ownership

Company	Insider Ownership
CORT Corcept Therapeutics	20.80%
JAZZ Jazz Pharmaceuticals	4.20%
MDCO Medicines	8.41%
RPRX Royalty Pharma	18.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CORT Corcept Therapeutics	300	106.05 million	83.30 million	Optionable
JAZZ Jazz Pharmaceuticals	3,200	60.51 million	57.92 million	Optionable
MDCO Medicines	62	79.72 million	N/A	Optionable
RPRX Royalty Pharma	80	562.24 million	477.83 million	Optionable

MDCO, RPRX, CORT, and JAZZ Headlines

Recent News About These Companies

Merit Financial Group LLC Invests $252,000 in Royalty Pharma plc (NASDAQ:RPRX)

June 13 at 3:43 AM | marketbeat.com

GAMMA Investing LLC Buys 77,751 Shares of Royalty Pharma plc (NASDAQ:RPRX)

June 13 at 3:18 AM | marketbeat.com

Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week High - Here's Why

June 12 at 12:19 PM | marketbeat.com

Handelsbanken Fonder AB Decreases Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

June 12 at 5:48 AM | marketbeat.com

RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives

June 10, 2025 | msn.com

Pallas Capital Advisors LLC Acquires 8,113 Shares of Royalty Pharma plc (NASDAQ:RPRX)

June 10, 2025 | marketbeat.com

Wedge Capital Management L L P NC Takes Position in Royalty Pharma plc (NASDAQ:RPRX)

June 8, 2025 | marketbeat.com

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | globenewswire.com

Ameriprise Financial Inc. Reduces Position in Royalty Pharma plc (NASDAQ:RPRX)

June 4, 2025 | marketbeat.com

Royalty Pharma plc (NASDAQ:RPRX) On An Uptrend: Could Fundamentals Be Driving The Stock?

June 2, 2025 | finance.yahoo.com

Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by California State Teachers Retirement System

May 31, 2025 | marketbeat.com

Mackenzie Financial Corp Buys 9,313 Shares of Royalty Pharma plc (NASDAQ:RPRX)

May 31, 2025 | marketbeat.com

111 Capital Purchases New Shares in Royalty Pharma plc (NASDAQ:RPRX)

May 30, 2025 | marketbeat.com

Lansforsakringar Fondforvaltning AB publ Makes New Investment in Royalty Pharma plc (NASDAQ:RPRX)

May 30, 2025 | marketbeat.com

9,329 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by GF Fund Management CO. LTD.

May 27, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 350,315 Shares of Royalty Pharma plc (NASDAQ:RPRX)

May 27, 2025 | marketbeat.com

Tidal Investments LLC Lowers Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

May 27, 2025 | marketbeat.com

Squarepoint Ops LLC Sells 242,051 Shares of Royalty Pharma plc (NASDAQ:RPRX)

May 26, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

May 26, 2025 | marketbeat.com

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Janus Henderson Group PLC

May 26, 2025 | marketbeat.com

University of Texas Texas AM Investment Management Co. Buys New Stake in Royalty Pharma plc (NASDAQ:RPRX)

May 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCO, RPRX, CORT, and JAZZ Company Descriptions

Corcept Therapeutics NASDAQ:CORT

$70.06 -1.12 (-1.57%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$70.12 +0.06 (+0.09%)

As of 06/13/2025 07:53 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Jazz Pharmaceuticals NASDAQ:JAZZ

$108.50 -1.79 (-1.62%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$104.58 -3.92 (-3.61%)

As of 06/13/2025 07:05 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Medicines NASDAQ:MDCO

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Royalty Pharma NASDAQ:RPRX

$34.84 -0.43 (-1.22%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$34.66 -0.18 (-0.50%)

As of 06/13/2025 06:52 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time